Drug & supplement interaction

Immunoaugmentative Therapy + Isatuximab-Irfc

Isatuximab-Irfc brand name: Sarclisa.

No Known Interaction
Medically reviewed by · Updated July 2026 · Pair last verified Sep 13, 2026
The bottom line No known interaction

We found no known interaction between Immunoaugmentative Therapy and Isatuximab-Irfc in our sources. Absence of a documented interaction is not the same as proven safety, and does not guarantee one does not exist. Do not start, stop, or change a medication or supplement based on this page; confirm with your pharmacist or doctor first. Additionally, although there is no interaction, the two are separately associated with some of the same side effects, which would make a new symptom harder to attribute to one or the other.

Know someone interested in this? Share
Facebook Post Reddit Email
On this page
Interaction report

Immunoaugmentative Therapy and Isatuximab-Irfc

We checked these two against our interaction database. Here is what we found.

No Known Interaction Found

We did not find a documented interaction between Isatuximab-Irfc and Immunoaugmentative Therapy in our sources. This does not guarantee that the combination is completely free of risk — research on Immunoaugmentative Therapy alongside specific medications may be limited.

Worth understanding: our licensed dataset holds no drug-interaction record for Immunoaugmentative Therapy at all — not against Isatuximab-Irfc, and not against any other medication we track. This verdict therefore rests on the absence of any recorded data, not on research that looked at this combination and found nothing. We cannot rule an interaction out.

Immunoaugmentative Therapy is a treatment rather than something you take. Tell whoever provides it which medicines you use, and ask your prescriber whether it is appropriate for your health and treatment. Do not stop a prescribed medicine on your own.

Always talk with your pharmacist or doctor before making changes to your medications or supplements, particularly if you take several medications or have an ongoing health condition.

Immunoaugmentative Therapy safety at a glance

Immunoaugmentative... overall Avoid IAT is unproven, not standardized, and carries infection and other risks; it is not recommended.
Pregnancy Avoid There is no safety data; avoid this unproven injectable therapy during pregnancy.
Breastfeeding Avoid No safety information exists; avoid while breastfeeding.

Safety guidance is general; always confirm with your pharmacist or doctor for your situation.

Still wondering about combining Isatuximab-Irfc and Immunoaugmentative Therapy? Ask Dr. Brian Staiger, PharmD, BCPS directly ›
What to actually watch for

No Interaction Found — But Data Suggests Immunoaugmentative Therapy and Isatuximab-Irfc May Share Several of the Same Side Effects

This is not an interaction. Neither one changes how your body handles the other, and nothing here says they react together. What our sources do show is that each has separately been linked to the effects below — so having Immunoaugmentative Therapy while taking the medicine can make those effects more likely to turn up, and harder to pin on one or the other if they do. One of them is worth acting on rather than waiting out — marked below.

  • A higher chance of infection Worth acting on Additional detail

    Immunoaugmentative Therapy

    “Immunoaugmentative therapy has never been thoroughly evaluated in clinical research. Case reports suggest that subcutaneous immunoaugmentative therapy can cause fatigue, flu-like illness, pain at the injection site, generalized pain, and swelling.”

    Immunoaugmentative Therapy · Natural Medicines adverse-effect record, reported in fatigue.

    3 sources cited
    1. 102927. Pfeifer BL, Jonas WB. Clinical evaluation of "immunoaugmentative therapy (IAT)": an unconventional cancer treatment. Integr Cancer Ther. 2003;2(2):112-9. PubMed
    2. 102928. Green S. Immunoaugmentative therapy. An unproven cancer treatment. JAMA 199313;270(14):1719-23. DOI
    3. 102929. Questionable Methods of Cancer Management: Immuno-augmentative Therapy (IAT). CA Cancer Journal for Clinicians1991;41(6):357-64.

    “Subcutaneously, serious infections, such as HIV and hepatitis B, have been reported after receiving immunoaugmentative therapy. This has raised the concern that the products used in therapy may be derived from infected individuals, without undergoing adequate sterilization processes.”

    Immunoaugmentative Therapy · Natural Medicines adverse-effect record, reported in hepatitis.

    2 sources cited
    1. 102928. Green S. Immunoaugmentative therapy. An unproven cancer treatment. JAMA 199313;270(14):1719-23. DOI
    2. 102929. Questionable Methods of Cancer Management: Immuno-augmentative Therapy (IAT). CA Cancer Journal for Clinicians1991;41(6):357-64.

    Isatuximab-Irfc

    Listed in the ADVERSE REACTIONS section of the FDA label for Isatuximab-Irfc. Read the label on DailyMed ›

  • Swelling Additional detail

    Immunoaugmentative Therapy

    Recorded for Immunoaugmentative Therapy in the same Natural Medicines adverse-effect record shown under A higher chance of infection above.

    Isatuximab-Irfc

    Listed in the ADVERSE REACTIONS section of the FDA label for Isatuximab-Irfc. Read the label on DailyMed ›

  • Tiredness Additional detail

    Immunoaugmentative Therapy

    “Subcutaneously, fatigue has been reported after immunoaugmentative therapy.”

    Immunoaugmentative Therapy · Natural Medicines adverse-effect record, reported in fatigue.

    1 source cited
    1. 102927. Pfeifer BL, Jonas WB. Clinical evaluation of "immunoaugmentative therapy (IAT)": an unconventional cancer treatment. Integr Cancer Ther. 2003;2(2):112-9. PubMed

    Isatuximab-Irfc

    Listed in the ADVERSE REACTIONS section of the FDA label for Isatuximab-Irfc. Read the label on DailyMed ›

Reported for Immunoaugmentative Therapy but not commonly for Isatuximab-Irfc: liver problems.

Effects for Isatuximab-Irfc come from the ADVERSE REACTIONS section of its FDA label; effects for Immunoaugmentative Therapy come from the Natural Medicines adverse-effect record, quoted above. Wording is matched across sources by our own clinical vocabulary, so treat this as a prompt to pay attention, not a diagnosis.

Overlapping uses

What Isatuximab-Irfc Is Prescribed For, and What Immunoaugmentative Therapy Has Been Studied For

These two come up together because they touch the same health topic — not because they do the same job. Isatuximab-Irfc is a prescription medicine with approved uses on its FDA label. Immunoaugmentative Therapy is a treatment: what follows is what researchers have looked at it for, and how strong that evidence is.

Isatuximab-Irfc is prescribed for: Isatuximab-irfc injection is used to treat multiple myeloma (a cancer of plasma cells in the bone marrow) in adult patients. It is always given alongside other medicines — never alone. Sarclisa Escena (the subcutaneous form) is approved in three combinations: with pomalidomide and dexamethasone for patients who have had at least one prior treatment including lenalidomide and a proteasome inhibitor; with carfilzomib and dexamethasone for relapsed or refractory multiple myeloma after one to three prior treatments; and with bortezomib, lenalidomide, and dexamethasone for newly diagnosed multiple myeloma in adults who are not eligible for an autologous stem cell transplant (a procedure using a patient's own stem cells). Intravenous isatuximab-irfc (Sarclisa) is used in the same combinations.

Immunoaugmentative Therapy has been studied for:

  • Cancer studied, not established Immunoaugmentative Therapy has been studied for this. Natural Medicines rates the evidence: Insufficient Reliable Evidence To Rate Read what the research shows

    Immunoaugmentative Therapy for cancer

    A retrospective evaluation of 46 cancer patients consecutively treated at an immunoaugmentative therapy clinic in Mexico suggests that this therapy does not alter the course of cancer or provide any measurable benefits. The validity of this finding is limited by the retrospective nature of the chart review.

    2 sources cited
    1. 102927. Pfeifer BL, Jonas WB. Clinical evaluation of "immunoaugmentative therapy (IAT)": an unconventional cancer treatment. Integr Cancer Ther. 2003;2(2):112-9. PubMed
    2. 102928. Green S. Immunoaugmentative therapy. An unproven cancer treatment. JAMA 199313;270(14):1719-23. DOI

Effectiveness ratings and the research summaries above are the verbatim record from the Natural Medicines database, which grades evidence from “Effective” down to “Insufficient Reliable Evidence To Rate”. A rating below the top of that scale means researchers have looked at it — not that it works, and never that it can stand in for a prescribed medicine. Do not stop or replace Isatuximab-Irfc on your own; if you are taking Immunoaugmentative Therapy for the same health topic, tell your prescriber, especially if the medicine is being adjusted to a target.

How much people look this up

Where Immunoaugmentative Therapy and Isatuximab-Irfc Sit Against Everything Else

Out of every supplement and medication people look up on HelloPharmacist, here is where these two land this week — and which way each has been moving.

Supplement Immunoaugmentative Therapy
Steady interest

#822 of 1,452 supplements looked up here in the last 7 days

29 days ago today
Medication Isatuximab-Irfc
Top 25%

#707 of 2,830 medications looked up here in the last 7 days

29 days ago today

Position among everything looked up on this site, not a measure of how commonly either one is used or how important it is. A supplement can climb this list because of a news story. It counts every request to the page, automated ones included, and nothing here identifies anyone.

Where does our data come from?
  • Source: the Natural Medicines (TRC Healthcare) clinical database — the evidence-graded professional reference for herb & supplement interactions.
  • Citation library: 103,510 references behind our interaction content, 65,311 of them resolved to verified PubMed/DOI sources. See every Immunoaugmentative Therapy reference on this page ↓
  • Freshness: we automatically re-check this combination every week — this pair was last verified September 13, 2026. The Immunoaugmentative Therapy and Isatuximab-Irfc records this page draws on were last updated July 10, 2026.
  • What “no known interaction” means: no documented interaction in the sources above — not a guarantee of safety. Supplements are studied far less than prescription drugs, so we say exactly what the evidence supports, and nothing more.
Data structure & sourcing designed and verified by .
Treatment approach

About Immunoaugmentative Therapy

What is Immunoaugmentative Therapy?

  • Cancer (as an alternative therapy)
  • Attempts to boost the immune system
  • Tumor reduction claims

Immunoaugmentative Therapy (IAT) is an unproven alternative cancer treatment, not a dietary supplement or herb. It involves injecting blood-derived protein mixtures, but there is no reliable scientific evidence that it treats cancer or any other disease, and it carries real safety risks. Talk to your oncologist before considering any alternative cancer therapy.

Not applicable (this is a treatment procedure, not a plant or herb) · Injections of blood-derived protein fractions given at a treatment clinic

An interaction check asks whether these two react with each other — it does not ask whether Immunoaugmentative Therapy is a good idea for someone in your situation. Here is what our Immunoaugmentative Therapy record says about it on its own.

Immunoaugmentative Therapy: dosing

There is no established or standardized dose for Immunoaugmentative Therapy, and it is not a product you can buy as a supplement. It was administered only at specific clinics following protocols that were never validated by mainstream science.HelloPharmacist does not recommend IAT.

From our Immunoaugmentative Therapy monograph — the full record covers uses, side effects and every documented interaction.

Read the full Immunoaugmentative Therapy monograph & all interactions
Medication

About Isatuximab-irfc Injection

What Is Isatuximab-irfc Injection Used For?

Brand name: Sarclisa

Isatuximab-irfc injection is used to treat multiple myeloma (a cancer of plasma cells in the bone marrow) in adult patients. It is always given alongside other medicines — never alone.

Sarclisa Escena (the subcutaneous form) is approved in three combinations: with pomalidomide and dexamethasone for patients who have had at least one prior treatment including lenalidomide and a proteasome inhibitor; with carfilzomib and dexamethasone for relapsed or refractory multiple myeloma after one to three prior treatments; and with bortezomib, lenalidomide, and dexamethasone for newly diagnosed multiple myeloma in adults who are not eligible for an autologous stem cell transplant (a procedure using a patient's own stem cells). Intravenous isatuximab-irfc (Sarclisa) is used in the same combinations.

See full Isatuximab-irfc Injection drug information
Keep checking

Other Drugs & Immunoaugmentative Therapy

Browse every other medication we’ve checked against Immunoaugmentative Therapy — both the ones with a known interaction and the ones without. Select any drug for the full detail.

0Major
0Moderate
0Minor
2,829No known interaction
2,829 No interaction
No interaction 2,829 drugs checked — show the list

We also checked Immunoaugmentative Therapy against these medications and found no known interaction in our sources. Open any page to confirm.

Showing the 60 most looked-up of 2,829 medications checked with no known interaction — see the full Immunoaugmentative Therapy list.

See the full Immunoaugmentative Therapy interactions page
See every supplement checked against Isatuximab-Irfc, ranked by severity
Evidence & sources

Immunoaugmentative Therapy References

The 3 references that drive our Immunoaugmentative Therapy monograph and interaction data, from the evidence-graded Natural Medicines (TRC Healthcare) database. Citations with a link open the study on PubMed or the publisher’s site.

  1. Pfeifer BL, Jonas WB. Clinical evaluation of "immunoaugmentative therapy (IAT)": an unconventional cancer treatment. Integr Cancer Ther. 2003;2(2):112-9. PubMed
  2. Green S. Immunoaugmentative therapy. An unproven cancer treatment. JAMA 199313;270(14):1719-23. DOI
  3. Questionable Methods of Cancer Management: Immuno-augmentative Therapy (IAT). CA Cancer Journal for Clinicians1991;41(6):357-64.

Medication overviews come from MedlinePlus (NIH); supplement label data from the NIH Dietary Supplement Label Database. Content is written and reviewed by licensed HelloPharmacist pharmacists — see our data sources and editorial standards.

Pharmacist Counseling Corner

Having Immunoaugmentative Therapy While Taking Isatuximab-Irfc: Common Questions

Is it safe to have Immunoaugmentative Therapy while taking Isatuximab-Irfc?
We do not list a known interaction between Immunoaugmentative Therapy and Isatuximab-Irfc. That does not guarantee the combination is risk-free, so confirm with your pharmacist or doctor — especially if you take other medications or have a health condition.
Do Immunoaugmentative Therapy and Isatuximab-Irfc have any of the same side effects?
Yes — our sources link each of them separately to 3 of the same effects. That is not an interaction: neither changes how your body handles the other. It does mean that if one of those effects turns up, it can be harder to tell which one is behind it. They are listed on this page with the source behind each.
Are Immunoaugmentative Therapy and Isatuximab-Irfc used for the same thing?
They overlap in purpose, which usually means the real question is whether you need both rather than whether they are safe together. This page lists the shared uses and how strong the evidence is for Immunoaugmentative Therapy in each. That is a conversation for your prescriber, especially if Isatuximab-Irfc is being adjusted to a target.

Written and reviewed by the HelloPharmacist editorial staff. Our editorial policy

Where next

Keep Exploring

Immunoaugmentative Therapy monograph Uses, safety profile, and every drug interaction in one place Isatuximab-irfc Injection drug information The full plain-English guide to this medication Isatuximab-Irfc supplement interactions Every supplement checked against Isatuximab-Irfc, ranked by severity Supplement interaction checker Check any supplement or product against your medications Browse medications A–Z Every drug we’ve checked against herbs & supplements References The 3 citations behind this page Ask a pharmacist Free, personal answer from our licensed team

Still Have a Question About Isatuximab-Irfc and Immunoaugmentative Therapy?

Our pharmacists answer your medication & supplement questions — free.

Ask a pharmacist

This information is for education only and is not a substitute for professional medical advice. Always check with your pharmacist or doctor before starting, stopping, or combining supplements and medications.